Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Tag: clinical trials
All
Latest
All
Latest
Neuromod’s Tinnitus Treatment Device Validated by Clinical Trial Results
Nature Communications published peer-reviewed results of Neuromod's TENT-A3 clinical trial, validating its tinnitus treatment device, Lenire.
All
Latest
Clinical Trial of Gene Therapy for Genetic Hearing Loss Gets Positive Results
The trial demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF gene therapy administration in the first participant.
Auris Medical Completes Enrollment in Phase 2 Study for Vertigo Drug
The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.
Read More
Otonomy Announces Positive Top-Line Results from Tinnitus Drug Trial
The trial reportedly achieved its objectives by demonstrating a positive clinical signal for OTO-313 based on a TFI responder analysis, with a favorable safety profile, according to the company.
Read More
Frequency Therapeutics Announces Clinical Data from Auditory Drug
FX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL).
Read More
Sensorion Announces Updated Timelines for Phase 2 Study of Hearing Loss Drug
Sensorion (FR0012596468 – ALSEN) a clinical-stage biotech company which specializes in the...
Read More
Akouos Announces Gene Therapy to Treat Genetic Hearing Loss
AK-OTOF is intended to treat individuals with sensorineural hearing loss due to mutations in the OTOF gene, who typically have severe hearing loss in both ears from birth, by promoting the expression of normal, functional otoferlin protein in affected cells of the cochlea.
Read More
Sensorion Receives IND Clearance from FDA on Hearing Loss Drug
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Otonomy Initiates Clinical Trial for Tinnitus Drug
The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus.
Read More
Audion Therapeutics and Regain Consortium Report Positive Phase I Results from Drug to Treat SNHL
LY3056480 mediated Notch inhibition is aimed at regeneration of inner ear sensory hair cells that are lost with advancing age.
Read More
Otonomy Presents Data on OTO-413 Therapy for Hearing Loss
These preclinical data, demonstrating the potential of intratympanic BDNF to repair cochlear synaptopathy—an underlying cause of hearing loss including speech-in-noise hearing difficulty—are being presented as part of the Society for Neuroscience (SfN) Annual Meeting in San Diego, November 3-7, 2018.
Read More
NF2 Trial: An Interview with Rick Friedman, MD, PhD
Hearing Review interviewed Rick Friedman, MD, PhD, about NF2 and an NF2 clinical that is underway in Los Angeles and at 12 other sites in the US. The trial uses the chemotherapy drug Avastin (bevacizumab) as a potential therapy for shrinking NF2 tumors, or stemming their growth.
Read More
Drug Trial Results Offer Hope for Ménière’s, Tinnitus Patients
Otonomy, which develops and commercializes therapeutics for ear diseases and disorders, reported that its development of investigational drugs to help patients with Ménière’s disease and tinnitus, have had positive results in clinical trials.
Read More
Auris Medical Begins Phase 3 Trial for Sudden Deafness Drug
Auris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Read More
Clinical Trial Tests Remote Care for Cochlear Implant Users
The University of Southampton Auditory Implant Service has launched a new clinical trial involving 60 patients, half of whom will use an online care package to determine whether the routine annual clinic check-up of hearing and device status can be replaced with a personalized online version.
Read More